Effects Of Oral Administration Of Type II Collagen On Rheumatoid Arthritis

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 65+
Notes for this study:
A study in 60 people with advanced rheumatoid arthritis given supplementation of solubilized collagen (0.1mg for one month then 1mg for the next) noted a reduction in joint pain and stiffness to a degree greater than placebo, with four subjects reporting resolution of symptoms dependent on supplementation (as symptoms reemerged after three months supplement cessation).

Treatment Of Rheumatoid Arthritis With Oral Type II Collagen. Results Of A Multicenter, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 228
Gender Both Genders
Age Range 45-64
Notes for this study:
Supplementation of four doses of CII to rheumatic patients (20mcg, 100mcg, 500mcg, or 2.5mg) over 24 weeks noted that the lower doses were associated with higher response rates than the higher doses, with the 19% response seen in placebo being outperformed by a 39% response in the 20mcg group (25% response in 2.5mg was not statistically significant).

Response was determined by at least a 30% reduction in joint soreness with responses on ACR and the Paulus criteria, and when looking only at the 30% reduction in pain all treatment groups (excluding ACR and Paulus) performed somewhat equally.

IgA and IgG antibodies were detected only in a few subjects, and appeared to predict responsiveness to therapy at all doses despite their specificity to CII or overall amounts being affected.

A Pilot Trial Of Oral Type II Collagen In The Treatment Of Juvenile Rheumatoid Arthritis

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 10
Gender Both Genders
Age Range 7-12, 13-17
Notes for this study:
Oral supplementation of CII in young subjects with juvenile rheumatoid arthritis appeared to have benefits in reducing symptoms over the course of three months of supplementation when compared to baseline in 8/10 subjects with one remission (although spontaneous remission is possible with untreated juvenile rheumatism); there was no placebo group for comparison.